Inflamed synovial tissue stromal cell markers

Inflamed synovial tissue stromal cell markers refer to a collection of proteins used to identify and characterize the heterogeneous populations of fibroblast-like synoviocytes (FLS) that drive joint pathology in inflammatory conditions such as rheumatoid arthritis. Key markers include Fibroblast Activation Protein alpha (FAP), Thy-1 membrane glycoprotein (THY1), Podoplanin (PDPN), and Cadherin-11 (CDH11), which distinguish between functionally distinct fibroblast subsets located in the synovial lining and sublining layers (Croft et al., 2019 [1]). In the inflamed synovium, FAP+THY1- fibroblasts in the lining layer are primarily responsible for cartilage and bone destruction through the secretion of matrix metalloproteinases, whereas FAP+THY1+ fibroblasts in the sublining layer drive persistent inflammation by producing pro-inflammatory cytokines and recruiting immune cells (Zhang et al., 2019 [2]). These markers are significant therapeutic targets because they allow for the potential selective depletion or modulation of pathogenic stromal cells without broad immunosuppression. For example, targeting Cadherin-11 (CDH11) with monoclonal antibodies like RG6125 has been explored to disrupt the invasive behavior of the synovial pannus (Lee et al., 2007 [5]). Despite their promise, therapeutic development faces challenges, including the need to maintain the homeostatic functions of the synovium, such as joint lubrication and nutrient exchange, while specifically inhibiting the inflammatory phenotype.

Other names

Synovial fibroblast markersFibroblast-like synoviocyte markersFLS markersSynovial stromal markersRA stromal cell markers

Targeting these markers typically involves the use of monoclonal antibodies to disrupt cell-cell adhesion, inhibit enzymatic activity (e.g., FAP protease activity), or deplete specific pathogenic fibroblast subsets to reduce joint inflammation and erosion.